+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

D-24851, a novel synthetic tubulin inhibitor, exerts superior in vivo antitumoral activity to paclitaxel or vincristine, efficacy against multidrug resistant tumors, and lacks neurotoxicity



D-24851, a novel synthetic tubulin inhibitor, exerts superior in vivo antitumoral activity to paclitaxel or vincristine, efficacy against multidrug resistant tumors, and lacks neurotoxicity



Proceedings of the American Association for Cancer Research Annual Meeting (41): 303




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034678804

Download citation: RISBibTeXText


Related references

D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Research 61(1): 392-399, 2001

Potent in vivo antitumor activity of D-24851, a novel tubulin inhibitor, in human xenografts and antimetastatic effect in the Renca model. Proceedings of the American Association for Cancer Research Annual Meeting 42: 370, 2001

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proceedings of the National Academy of Sciences of the United States of America 96(10): 5686-5691, 1999

BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Research 64(13): 4621-4628, 2004

In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. Journal of Controlled Release 112(3): 312-319, 2006

Potentiation of etoposide and vincristine by two synthetic 1,4-dihydropyridine derivatives in multidrug-resistant and atypical multidrug-resistant human cancer cells. Anti-Cancer Drug Design 6(1): 47-57, 1991

Liposome-encapsulated vincristine exhibits significant in vivo anti-tumor activity against vincristine-resistant human solid tumors. Proceedings of the American Association for Cancer Research Annual Meeting 44: 747, 2003

A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Biochemical Pharmacology 97(1): 51-61, 2015

Modulation of paclitaxel metabolism and pharmacodynamics by quercetin Potential for enhanced drug efficacy against multidrug resistant tumors. Pharmaceutical Research (New York) 14(11 Suppl. ): S553, 1997

Selective, covalent modification of certain beta-tubulin isotypes by T900607, a novel antitumor agent with efficacy against multidrug resistant tumors. Proceedings of the American Association for Cancer Research Annual Meeting (41): 302, 2000

A Promising Microtubule Inhibitor Deoxypodophyllotoxin Exhibits Better Efficacy to Multidrug-Resistant Breast Cancer than Paclitaxel via Avoiding Efflux Transport. Drug Metabolism and Disposition: the Biological Fate of Chemicals 46(5): 542-551, 2018

Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clinical Cancer Research 8(3): 670-678, 2002

Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clinical Cancer Research 12(11 Pt 1): 3459-3469, 2006

The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Molecular Pharmacology 52(4): 613-622, 1997

Zerumbone, a cyclic sesquiterpene, exerts antimitotic activity in HeLa cells through tubulin binding and exhibits synergistic activity with vinblastine and paclitaxel. Cell Proliferation 52(2): E12558, 2019